Approval process for generic drugs will likely be suspended to a 12-month

Korea will set up a system to suspend the approval process of a generic drug when the original U.S. developer files a complaint about patent violation against a generic maker that applies for product approval, according to an official at the Korea Food and Drug Administration.

In a phone call with the Yakup Shinmoon on August 27, the official affirmed that a patent infringement suit will aut...